Sana Biotechnology (SANA) Income from Continuing Operations (2020 - 2026)
Sana Biotechnology recorded quarterly Income from Continuing Operations of 47663000.0 in Q1 2026, up 20.46% quarter-over-quarter from 59923000.0 in Q4 2025, and up 3.98% year-over-year from 45839148.94 in Q1 2025.
Sana Biotechnology's Income from Continuing Operations history runs 7 years deep, the most recent figure standing at 47663000.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations rose 3.98% year-over-year to 47663000.0; the TTM figure through Mar 2026 stood at 244496000.0 (down 19.73% YoY), while the FY2025 annual figure was 246471000.0, up 6.02% from the prior year.
- Income from Continuing Operations came in at 47663000.0 for Q1 2026 at Sana Biotechnology, up from 59923000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 681000.0 in Q3 2023 to a low of 113915000.0 in Q2 2023.
- A 5-year average of 65199470.59 and a median of 59923000.0 in 2025 frame the typical range for Income from Continuing Operations.
- Across the five-year window, Income from Continuing Operations surged 100.8% in 2023 and plunged 8790.46% in 2024, its largest moves.
- Sana Biotechnology's Income from Continuing Operations stood at 80175000.0 in 2022, then slipped by 9.63% to 87893000.0 in 2023, then soared by 44.01% to 49210000.0 in 2024, then declined by 21.77% to 59923000.0 in 2025, then rose by 20.46% to 47663000.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 47663000.0, 59923000.0, and 42512000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -8.40 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.40 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Sana Biotechnology | 890.09 Mn | 890.09 Mn | - | -47.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -47.66 Mn |
| Dec 31, 2025 | -59.92 Mn |
| Sep 30, 2025 | -42.51 Mn |
| Jun 30, 2025 | -94.40 Mn |
| Mar 31, 2025 | -49.64 Mn |
| Dec 31, 2024 | -49.21 Mn |
| Sep 30, 2024 | -59.18 Mn |
| Jun 30, 2024 | -46.17 Mn |
| Mar 31, 2024 | -107.69 Mn |
| Dec 31, 2023 | -87.89 Mn |
| Sep 30, 2023 | 681,000.00 |
| Jun 30, 2023 | -113.92 Mn |
| Mar 31, 2023 | -82.08 Mn |
| Dec 31, 2022 | -80.18 Mn |
| Sep 30, 2022 | -85.01 Mn |
| Jun 30, 2022 | -72.27 Mn |
| Mar 31, 2022 | -31.35 Mn |
| Dec 31, 2021 | -111.01 Mn |
| Sep 30, 2021 | -83.27 Mn |
| Jun 30, 2021 | 18.68 Mn |
| Mar 31, 2021 | -180.63 Mn |
| Dec 31, 2020 | -113.20 Mn |
| Sep 30, 2020 | -51.50 Mn |
| Jun 30, 2020 | -87.83 Mn |
| Mar 31, 2020 | -32.88 Mn |